Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.
Continuous innovation is required in various technological aspects to effectively manage the challenges of vast clinical data.
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.
A collaborative exercise with 16 health care organizations nets millions in savings.
Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.
Here are the top 5 biosimilar articles for the week of November 25, 2024.
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.
Unbranded biologics primarily serve to uphold inflated list prices, typically prompted by loss of exclusivity, aiming to safeguard market share and counter biosimilar competition, although forthcoming legislative changes targeting high drug costs could lessen their significance moving forward.
An internationally recognized authority on biosimilar development discusses varieties of copy biologics in India and the need to distinguish these from true biosimilars.
Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
In this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.
The potential and promise of biosimilars are there—it is up to all of us to bring it to reality so we can expand access to safe, effective, affordable drugs for women.
Changes in federal and state policy can help liberate the savings potential in biosimilars and broaden investment in our health care system.
Two experts in biosimilar intellectual property (IP) law break down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains what health organizations and health systems can do to better manage and instill confidence in biosimilars.
Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
Health literacy was categorized as problematic in 36.2% of patients and insufficient in 15.1%.
The House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.
Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Intellectual property law attorneys from the Washington, DC, offices of McDermott Will & Emery LLP, discuss 5 of the most significant trends in biologics litigation that have emerged in recent months.
Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.
Despite improvements in biosimilar education efforts for future health care professionals, payer policies need a major revamp to ensure that biosimilar use is encouraged, according to Pfizer's Mike Gladstone.